Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Phase II Study of Moderate-dose Hypofractionated RT Combined With Pembrolizumab for HCC With Diffuse Tumor Thrombosis
- Status
- RECRUITING
- Phase
- PHASE2
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of BV-AVD in People With Bulky Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma
- Status
- RECRUITING
- Phase
- PHASE2
PBI-MST-01 (NCT04541108) Substudy AZN-05: Intratumoral Microdosing of Rilvegostomig, Volrustomig, Sabestomig, and AZD9592 in HNSCC
- Status
- RECRUITING
- Phase
- EARLY_PHASE1
ALPINE: Maintenance Letrozole/Abemaciclib
- Status
- RECRUITING
- Phase
- PHASE2
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC
- Status
- RECRUITING
- Phase
- PHASE2
CARE1 Pragmatic Clinical Trial
- Status
- RECRUITING
- Phase
- PHASE3
PSMA Therapy and Immunotherapy in Kidney Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
- Status
- RECRUITING
- Phase
- PHASE3
Study of Neoadjuvant Enfortumab Vedotin and Pembrolizumab in Cisplatin-eligible Upper Tract Urothelial Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
- Status
- RECRUITING
- Phase
- PHASE2
Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer
- Status
- RECRUITING
- Phase
- PHASE2
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
- Status
- RECRUITING
- Phase
- PHASE3
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
- Status
- RECRUITING
- Phase
- PHASE1